Shane Lea - Cellectar Biosciences Chief Officer
| CLRB Stock | USD 1.54 0.01 0.65% |
Insider
Shane Lea is Chief Officer of Cellectar Biosciences
| Address | 100 Campus Drive, Florham Park, NJ, United States, 07932 |
| Phone | 608 441 8120 |
| Web | https://www.cellectar.com |
Cellectar Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.66) % which means that it has lost $1.66 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.9667) %, meaning that it created substantial loss on money invested by shareholders. Cellectar Biosciences' management efficiency ratios could be used to measure how well Cellectar Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At present, Cellectar Biosciences' Return On Capital Employed is projected to increase significantly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 29.41, whereas Return On Tangible Assets are projected to grow to (2.99). At present, Cellectar Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2 M, whereas Non Currrent Assets Other are forecasted to decline to about 28.3 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| BBA CPA | Lumos Pharma | 57 | |
| Peter MBA | Bio Path Holdings | 75 | |
| Alan MacKenzie | Bio Path Holdings | N/A | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Steven JD | Longboard Pharmaceuticals | 59 | |
| Gus Cardenas | Longboard Pharmaceuticals | N/A | |
| Anthony MBA | Capricor Therapeutics | 38 | |
| Megan Knight | Longboard Pharmaceuticals | N/A | |
| Bradley JD | Lumos Pharma | 45 | |
| Xavier Avat | Capricor Therapeutics | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| Linda Marbn | Capricor Therapeutics | 61 | |
| Thomas Walker | Bio Path Holdings | N/A | |
| Jeffery MD | Bio Path Holdings | N/A | |
| Michael MSBA | NextCure | 63 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| Lisa Miller | Lumos Pharma | N/A | |
| MBA CMA | Pulmatrix | 69 | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| Richard Hawkins | Lumos Pharma | 75 | |
Management Performance
| Return On Equity | -7.97 | ||||
| Return On Asset | -1.66 |
Cellectar Biosciences Leadership Team
Elected by the shareholders, the Cellectar Biosciences' board of directors comprises two types of representatives: Cellectar Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectar. The board's role is to monitor Cellectar Biosciences' management team and ensure that shareholders' interests are well served. Cellectar Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectar Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Sec | ||
| Andrei MD, Senior Medical | ||
| Shane Lea, Chief Officer | ||
| Chad CPA, CFO VP | ||
| Darrell Lea, Chief Officer | ||
| Jarrod Longcor, Senior Vice President - Corporate Development and Operations | ||
| James Caruso, CEO and President and Director |
Cellectar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellectar Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.97 | ||||
| Return On Asset | -1.66 | ||||
| Current Valuation | 43.42 M | ||||
| Shares Outstanding | 41.27 M | ||||
| Shares Owned By Insiders | 2.83 % | ||||
| Shares Owned By Institutions | 34.54 % | ||||
| Number Of Shares Shorted | 1.16 M | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 41.02 X | ||||
| EBITDA | (38.77 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.